Xena

What Xena does

XENA (legal entity XENA Intelligence) is a Germany-incorporated, US-piloting medical-AI company building a 3D surgical intelligence platform that converts standard MRI scans into radiologist-reviewed surgical roadmaps for gynecologic surgeons. The company's core technology is a proprietary Anatomical Foundation Model trained on clinical MRI data, which performs automated organ segmentation at sub-millimeter resolution and produces three integrated outputs: 3D Reconstruction (disease extent and organ relationships), Surgical Planning (interactive 3D review and dissection planning), and Intra-Op Guidance (live 3D spatial reference in the OR). Every output is reviewed by a US board-certified radiologist before reaching the surgeon, positioning the platform as a physician-in-the-loop intelligence layer rather than a standalone diagnostic tool.

The product is currently in pilot at US hospitals under a Research Use Only designation, with a multi-center prospective validation study enrolling at named sites including Hoag Hospital, UC San Diego Health, Mary Washington Healthcare, and Center for Pelvic Health. Indication coverage is sequenced as: endometriosis and adenomyosis live, fibroids next, gynecologic oncology on the roadmap, and broader soft-tissue surgery (urology, colorectal, abdominal) as a long-term architectural expansion on the same foundation model.

XENA's business model is a per-scan transaction fee billed under existing CPT codes, which the company states makes the procedure reimbursable from day one of commercial clearance, targeting hospital departments and surgeons rather than requiring new insurance coverage decisions. Commercial go-to-market is enterprise field sales to hospital systems, currently driven by clinical validation studies, surgeon champions, and a Request Demo engagement model. The company has one disclosed funding event (Techstars, August 2024, approximately $218K), 1-10 employees, and is founder-led by CEO Czuee Morey (PhD Neurobiology, University of Lausanne), CTO Deepali Godbole (M.Tech IIT Bombay, ex-J&J Medical), COO Mohamed Taha (PhD, École Centrale de Lyon, 3x healthcare AI founder with two prior FDA/CE clearances), and CMO Dr. Kurian Thott (Intuitive Surgical proctor and J&J Institute faculty).

Name

Xena

Legal name

XENA Intelligence

Website

https://xenadx.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

XENA builds an AI-powered 3D surgical intelligence platform that converts standard MRI scans into radiologist-reviewed surgical roadmaps for gynecologic surgeons, with endometriosis and adenomyosis live and broader soft-tissue applications on the roadmap. The company is pre-revenue and piloting at US hospitals under a Research Use Only designation.

Ownership category

akta.pro rank

Product category

AI Surgical Planning Software

NAICS

Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro industry

PRIMARYHLAHABAJ

Radiology AI, CAD & Advanced Visualization Software

Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment

SECONDARYHDAAAEAH

Medical Imaging AI

Hardware, Technology & Telecom/Artificial Intelligence & Machine Learning/Computer Vision & Video Analytics

SECONDARYHLAHADAG

Surgical Navigation, Tracking & Intraoperative Guidance (Ortho/Neuro/ENT)

Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment

SECONDARYHLAKAJAF

Minimally Invasive Gynecologic Surgery (Laparoscopy/Hysteroscopy)

Healthcare & Life Sciences/Specialist Medical Practice/Obstetrics & Gynecology (OB/GYN)

Keywords

• Surgical intelligence software
• MRI-based surgical planning
• Gynecologic surgery AI
• 3D anatomical reconstruction
• Preoperative surgical roadmap

Headquarters

HQ city

Mannheim

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. MRI-based surgical intelligence service: XENA generates revenue by processing MRI scans into 3D surgical roadmaps and surgical plans, billed under existing CPT billing codes. This makes the procedure reimbursable from day one, generating revenue for hospital departments and surgeons without requiring new insurance codes or coverage decisions.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

XENA converts standard MRI scans into AI-generated 3D surgical roadmaps for gynecologic surgeons, providing automated organ segmentation, disease mapping, and intraoperative guidance for endometriosis, fibroids, adenomyosis, and gynecologic oncology procedures. The platform delivers a 3D disease map, surgical plan with measured distances to critical structures, and live intraoperative reference, with all outputs reviewed by US board-certified radiologists before reaching the surgeon.

Product overview

XENA is a unified surgical intelligence platform that generates 3D surgical roadmaps from standard MRI scans. The platform consists of three integrated modules: 3D Reconstruction (automated organ segmentation and disease mapping), Surgical Planning (interactive 3D review and dissection planning), and Intra-Op Guidance (live 3D reference during procedures). All outputs are reviewed by a US board-certified radiologist before reaching the surgeon. The platform currently focuses on gynecology (endometriosis, adenomyosis, fibroids, gyn oncology) with roadmap for broader soft tissue surgery including urology and colorectal applications.

Differentiator

Problem solved

Functional benefit

Products and services

• 3D Reconstruction
• Surgical Planning
• Intra-Op Guidance

Quantifiable outcome

• 43% of surgeons changed their surgical plan after reviewing XENA's 3D anatomy map
• +3 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Partnerships

Four partnerships are on record, tiered core.

• Hoag Hospital (Hoag Orange County)coreStrategic or Co-development PartnerHoag Hospital is a clinical validation site and pilot location for XENA's technology. Dr. Marc Winter, a gynecologic surgeon at Hoag Hospital, is quoted as a clinical user of XENA and provides clinical validation endorsement. The partnership involves using XENA's 3D surgical planning for endometriosis cases.
• UC San Diego HealthcoreStrategic or Co-development PartnerUC San Diego Health is listed among the surgeons supporting XENA, indicating active clinical collaboration in the prospective validation study. Their involvement provides academic medical center credibility and surgical expertise to the validation program.
• Mary Washington HealthcarecoreStrategic or Co-development PartnerMary Washington Healthcare is a clinical validation site for XENA's multi-center US validation study. Dr. Kurian Thott, CMO of XENA, serves as Director of Minimally Invasive Surgery at Mary Washington Healthcare, creating a direct link between the company and this partner institution.
• Center for Pelvic HealthcoreStrategic or Co-development PartnerCenter for Pelvic Health is a clinical validation site supporting XENA, contributing to the prospective multi-center validation study and providing clinical expertise in pelvic surgery.

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Activ Surgical: Activ Surgical builds AI-driven real-time surgical intelligence and visualization for the operating room. It is a direct peer to Xena in applying AI/computer vision to intraoperative decision-making, though its focus is broader across laparoscopic procedures.
• Surgical Theater: Surgical Theater provides 3D VR-based surgical planning and visualization from imaging data. It is a direct peer to Xena in converting standard imaging into interactive 3D surgical roadmaps, with overlap in pre-operative planning use cases.
• Proprio Vision: Proprio uses AI and computer vision for surgical navigation and intraoperative guidance. It is a direct peer to Xena in computer-vision-driven surgical intelligence, with complementary data inputs (light field imaging vs MRI).
• Invenio Imaging: Invenio Imaging applies AI to intraoperative tissue imaging for pathology and surgical guidance. It is a direct peer in AI-driven surgical imaging analysis, with overlap in leveraging imaging data for clinical decision support.

Broad incumbents

• Brainlab: Brainlab is an established medical technology company specializing in surgical navigation, planning, and intraoperative guidance across multiple specialties. It is a broad incumbent that overlaps with Xena's surgical planning and intraoperative guidance capabilities, but as part of a much wider portfolio.
• Stryker: Stryker is a large medical device company with a broad surgical equipment and navigation portfolio, including Mako robotics and surgical planning tools. It is a broad incumbent that could enter or extend into AI-driven surgical intelligence for gynecology and soft tissue.
• Medtronic: Medtronic is a large medical device company with significant surgical navigation, robotics (Hugo), and digital surgery capabilities. It is a broad incumbent that competes in the broader surgical planning and intraoperative guidance market Xena addresses.
• Intuitive Surgical: Intuitive Surgical is the dominant surgical robotics company (da Vinci) with a growing digital and analytics portfolio. It is a broad incumbent whose installed base of robotic systems is a likely integration point for AI surgical planning layers like Xena's.

Emerging players

• Vicarious Surgical: Vicarious Surgical is developing next-generation robotic surgery systems with AI and VR components. It is an emerging player that intersects with Xena's surgical intelligence vision through its combination of robotics and AI-driven visualization.
• CMR Surgical: CMR Surgical (Versius robot) is an emerging surgical robotics company competing with Intuitive in minimally invasive surgery. It is an emerging player whose robotics platform is a potential integration target for AI surgical planning layers like Xena.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Xena